Literature DB >> 9055857

Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts.

D Bohl1, N Naffakh, J M Heard.   

Abstract

We investigated tetracycline regulation of gene expression in an experimental model relevant to gene therapy. Mouse primary myogenic cells were engineered for doxycycline-inducible and skeletal muscle-specific expression of the mouse erythropoietin (Epo) cDNA by using two retrovirus vectors. Gene expression increased 200 fold in response to both myogenic cell differentiation and doxycycline stimulation. After transplantation of transduced cells into mouse skeletal muscles, Epo secretion could be iteratively switched on and off over a five-month period, depending on the presence or the absence of doxycycline in the drinking water. We conclude that tetracycline regulation provides a suitable control system for adjusting the delivery of therapeutic proteins from engineered tissues over long periods of time.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9055857     DOI: 10.1038/nm0397-299

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  21 in total

Review 1.  Regulatable systems: applications in gene therapy and replicating viruses.

Authors:  S Agha-Mohammadi; M T Lotze
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles.

Authors:  Jing Chen; Wu-Li Yang; Ge Li; Ji Qian; Jing-Lun Xue; Shou-Kuan Fu; Da-Ru Lu
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

Review 3.  Drugs for increasing oxygen and their potential use in doping: a review.

Authors:  Aurelie Gaudard; Emmanuelle Varlet-Marie; Francoise Bressolle; Michel Audran
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

4.  Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential.

Authors:  U Baron; M Gossen; H Bujard
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

Review 5.  Gene therapy for rheumatoid arthritis.

Authors:  P D Robbins; C H Evans; Y Chernajovsky
Journal:  Springer Semin Immunopathol       Date:  1998

Review 6.  Gene therapy for rheumatoid arthritis. Theoretical considerations.

Authors:  Y Chernajovsky; A Annenkov; C Herman; K Triantaphyllopoulos; D Gould; H Dreja; S P Moyes; J L Croxford; R A Mageed; O L Podhajcer; D Baker
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

7.  Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation.

Authors:  G Rizzuto; M Cappelletti; D Maione; R Savino; D Lazzaro; P Costa; I Mathiesen; R Cortese; G Ciliberto; R Laufer; N La Monica; E Fattori
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

8.  The tetracycline-responsive promoter contains functional interferon-inducible response elements.

Authors:  A Rang; H Will
Journal:  Nucleic Acids Res       Date:  2000-03-01       Impact factor: 16.971

9.  Streptomyces-derived quorum-sensing systems engineered for adjustable transgene expression in mammalian cells and mice.

Authors:  Wilfried Weber; Ronald Schoenmakers; Manuela Spielmann; Marie Daoud El-Baba; Marc Folcher; Bettina Keller; Cornelia C Weber; Nils Link; Petra van de Wetering; Christoph Heinzen; Benoît Jolivet; Urs Séquin; Dominique Aubel; Charles J Thompson; Martin Fussenegger
Journal:  Nucleic Acids Res       Date:  2003-07-15       Impact factor: 16.971

10.  Adeno-associated viral vector-mediated hypoxia-regulated VEGF gene transfer promotes angiogenesis following focal cerebral ischemia in mice.

Authors:  F Shen; Y Fan; H Su; Y Zhu; Y Chen; W Liu; W L Young; G-Y Yang
Journal:  Gene Ther       Date:  2007-10-25       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.